Press releases

All press releases Regulatory

Regulatory press release 2024-12-04

Xspray publishes the final outcome of the rights issue

Regulatory press release 2024-12-02

Strong interest in Xspray Pharma AB’s rights issue – preliminary outcome is published

Regulatory press release 2024-11-14

Xspray publishes prospectus relating to the rights issue

Regulatory press release 2024-11-06

Interim Report Third Quarter 2024

Regulatory press release 2024-11-06

Xspray resolves on a rights issue of approximately SEK 135 million and raises a loan of SEK 100 million

Regulatory press release 2024-10-21

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2025

Press release 2024-09-19

Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

Regulatory press release 2024-08-07

Interim Report Second Quarter 2024

Regulatory press release 2024-07-26

Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development

Regulatory press release 2024-07-09

Xspray Pharma’s XS003 Study shows Matching Bioavailability to Tasigna at more than a 50% Lower Dose

IR contact

Kerstin Hasselgren, IRO / Senior Adviser

+46 (0)70 311 16 83

info@xspray.com

Subscribe